Page 1

SELLAS LIFE SCIENCES GROUP NEWS RELEASE SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update 11/12/2021 NEW YORK , Nov. 12 , 2021 ( GLOBE NEWSWIRE ) -- SELLAS Life Sciences Group , Inc. ( NASDAQ : SLS ) ( " SELLAS " or the " Company " ) , a late - stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications , today reported its financial results for the quarter ended September 30 , 2021 and provided a business update . " During the third quarter of 2021 , in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut - S ( GPS ) in acute myeloid leukemia ( AML ) patients , we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bone marrow transplant ( BMT ) who harbor minimal residual disease ( MRD ) , " said Angelos M. Stergiou , MD , SCD . h.c. , President and Chief Executive Officer of SELLAS . " We are excited to begin exploring GPS as a treatment option for this post - BMT population which , based on the retrospective outcomes data published earlier in the summer , remains an area of unmet need . We believe there is significant opportunity for GPS to become the key antileukemic vaccine immunotherapy in various AML settings , with the potential to treat patients who have undergone a BMT as well as patients who have achieved second remission in AML ( CR2 ) , the indication of our REGAL study . " Dr. Yair Levy , Director of Hematologic Malignancies at the Baylor University Medical Center , stated " I look forward to a clinical trial in transplanted patients that would address the high relapse rate among MRD positive ( MRD + ) AML patients . Although BMT remains the only truly curative treatment for AML patients with any significant disease risk , its benefit is limited by relapses in about 50 % of patients who enter transplant with MRD . The trial being planned by SELLAS would explore whether GPS could be a treatment option for a much larger population of AML patients - i.e. , those patients who have undergone BMT whose chances of remaining in remission could significantly improve as well as the large number of MRD + patients who have been shown to have a high relapse rate after BMT or who do 1